Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1,040
No. of companies carrying out R&D in Biotechnology;250 or more employees;93
No. of companies carrying out R&D in Biotechnology;Total;1,133
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;32
%Companies according to biotechnology used: Genetic code;250 or more employees;43
%Companies according to biotechnology used: Genetic code;Total;33
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;40
%Companies according to biotechnology used: Functional units;250 or more employees;51
%Companies according to biotechnology used: Functional units;Total;41
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;22
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;41
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;24
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;48
%Companies according to biotechnology used: Bioprocesses;250 or more employees;69
%Companies according to biotechnology used: Bioprocesses;Total;50
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;5
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;12
%Companies according to biotechnology used: Sub-cellular organisms;Total;6
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;24
%Companies according to biotechnology used: Bio-computing;250 or more employees;28
%Companies according to biotechnology used: Bio-computing;Total;24
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;13
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;13
%Companies according to biotechnology used: Nanobiotechnology;Total;13
%Companies according to biotechnology used: Other;Fewer than 250 employees;15
%Companies according to biotechnology used: Other;250 or more employees;8
%Companies according to biotechnology used: Other;Total;14
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;581
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;22
Companies in which biotechnology activities are: Main and/or exclusive;Total;603
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;155
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;18
Companies in which biotechnology activities are: A secondary line of business;Total;173
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;305
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;53
Companies in which biotechnology activities are: A tool necessary for production;Total;357
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;45
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;49
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;45
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;19
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;18
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;30
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;39
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;31
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;23
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;17
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;22
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;17
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;14
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;9
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;12
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;8,124
Personnel in R&D in biotechnology (no. of persons);250 or more employees;3,386
Personnel in R&D in biotechnology (no. of persons);Total;11,510
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;4,552
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;1,650
Personnel in R&D in biotechnology (no. of persons): Researchers;Total;6,202
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;3,572
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;1,736
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total;5,308
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4,363
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;2,026
Personnel in R&D in biotechnology (no. of persons): women;Total;6,389
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2,368
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;935
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total;3,304
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;1,995
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;1,090
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total;3,086
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;5,788.1
Personnel in R&D in biotechnology (FTE);250 or more employees;2,448.9
Personnel in R&D in biotechnology (FTE);Total;8,236.9
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3,364.3
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1,231.9
Personnel in R&D in biotechnology (FTE): Researchers;Total;4,596.1
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2,423.8
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;1,217.0
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total;3,640.8
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;3,197.5
Personnel in R&D in biotechnology (FTE): women;250 or more employees;1,501.0
Personnel in R&D in biotechnology (FTE): women;Total;4,698.5
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;1,803.7
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;708.8
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total;2,512.5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1,393.8
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;792.2
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total;2,186.0
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;558,184
Internal expenditure on R&D (thousands of euros);250 or more employees;211,247
Internal expenditure on R&D (thousands of euros);Total;769,431
1) By nature of the expense: Current expenses;Fewer than 250 employees;518,032
1) By nature of the expense: Current expenses;250 or more employees;201,684
1) By nature of the expense: Current expenses;Total;719,715
1.1) Remuneration to researchers;Fewer than 250 employees;154,555
1.1) Remuneration to researchers;250 or more employees;66,892
1.1) Remuneration to researchers;Total;221,447
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;72,617
1.2) Remuneration to technicians and assistants;250 or more employees;50,192
1.2) Remuneration to technicians and assistants;Total;122,809
1.3) Other current expenses;Fewer than 250 employees;290,860
1.3) Other current expenses;250 or more employees;84,599
1.3) Other current expenses;Total;375,459
2) By nature of the expense: Capital expenses;Fewer than 250 employees;40,152
2) By nature of the expense: Capital expenses;250 or more employees;9,563
2) By nature of the expense: Capital expenses;Total;49,715
2.1) Land and buildings;Fewer than 250 employees;6,661
2.1) Land and buildings;250 or more employees;2,860
2.1) Land and buildings;Total;9,521
2.2) Equipment and instruments;Fewer than 250 employees;24,465
2.2) Equipment and instruments;250 or more employees;6,001
2.2) Equipment and instruments;Total;30,466
2.3) Acquisition of specific R&D software;Fewer than 250 employees;1,157
2.3) Acquisition of specific R&D software;250 or more employees;653
2.3) Acquisition of specific R&D software;Total;1,810
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;7,869
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;49
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;7,919
1.1) By origin of the funds: Own funds;Fewer than 250 employees;385,847
1.1) By origin of the funds: Own funds;250 or more employees;105,066
1.1) By origin of the funds: Own funds;Total;490,913
1.2) By origin of the funds: From companies;Fewer than 250 employees;53,140
1.2) By origin of the funds: From companies;250 or more employees;29,409
1.2) By origin of the funds: From companies;Total;82,548
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;64,168
1.3) By origin of the funds: Public Administration funds;250 or more employees;32,641
1.3) By origin of the funds: Public Administration funds;Total;96,809
1.4) By origin of the funds: From Universities;Fewer than 250 employees;197
1.4) By origin of the funds: From Universities;250 or more employees;0
1.4) By origin of the funds: From Universities;Total;197
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;588
1.5) By origin of the funds: From non profit private institutions;250 or more employees;4,177
1.5) By origin of the funds: From non profit private institutions;Total;4,766
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;54,244
1.6) By origin of the funds: Foreign funds;250 or more employees;39,954
1.6) By origin of the funds: Foreign funds;Total;94,197
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;68,331
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;51,951
Purchase of R&D services in biotechnology (thousands of euros);Total;120,281
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;22,667
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;46,897
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;69,564
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;45,664
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;5,054
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;50,718
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;47
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;23
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;45
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;12
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;15
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;14
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;11
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;16
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;19
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;10
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;18
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;16
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;13
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;15
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;37
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;29
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;37
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;53
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;39
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;52
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;20
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;20
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;15
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;17
% Companies that have requested biotechnology patents in Biotechnology;Total;15
Number of patents requested;Fewer than 250 employees;525
Number of patents requested;250 or more employees;156
Number of patents requested;Total;681
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;24.9
% Companies with income of an international origin related to biotechnological activities;250 or more employees;18.4
% Companies with income of an international origin related to biotechnological activities;Total;24.3
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;6.00
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;1.00
% Turnover representing income of an international origin related to biotechnological activities;Total;1.00
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;45.20
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;73.10
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;59.60
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;54.80
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;26.90
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;40.40
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;89.00
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;72.50
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;80.40
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;7.50
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;24.90
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;16.50
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;2.20
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;2.30
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;2.20
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;1.40
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0.40
% Income of an international origin related with activities according to the classification: Other;Total;0.90